The estimated Net Worth of T. Alex Mc Pherson is at least $3.21 mil dollars as of 27 May 2011. T Pherson owns over 6,200 units of Novabay Pharmaceuticals Inc stock worth over $3,211 and over the last 17 years T sold NBY stock worth over $0.
T has made over 3 trades of the Novabay Pharmaceuticals Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently T bought 6,200 units of NBY stock worth $10,230 on 27 May 2011.
The largest trade T's ever made was buying 6,200 units of Novabay Pharmaceuticals Inc stock on 27 May 2011 worth over $10,230. On average, T trades about 197 units every 33 days since 2007. As of 27 May 2011 T still owns at least 6,700 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of T Pherson stock trades at the bottom of the page.
T's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 5980 HORTON STREET, SUITE 550, EMERYVILLE, CA, 94608.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... y Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: